Pyrazine

Pyrazine

SCHEMBL7056616

c1cc2nccnc2cn1.c1cnccn1

nearest known ligand 0.40

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
LMNA P02545 2/20 0.36
MAPT P10636 2/20 0.36
KDM4A O75164 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5C P41229 1/20 0.36
KDM4C Q9H3R0 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
KDM3A Q9Y4C1 1/20 0.36
MAPK1 P28482 2/20 0.36
KDM4E B2RXH2 1/20 0.34
NAPRT Q6XQN6 1/20 0.34
HCAR2 Q8TDS4 1/20 0.34
FGFR1 P11362 1/20 0.34
TSHR P16473 2/20 0.33
ADORA3 P0DMS8 2/20 0.33
HDAC8 Q9BY41 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL88851 0.95 KDM4A (0.39) HSP90AA1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL29428806 0.95 KDM4A (0.39) HSP90AA1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL30237822 0.95 KDM4A (0.39) HSP90AA1SMN1; SMN2NPC1RAB9ALMNA
SCHEMBL14856779 0.78 ALDH1A1 (0.40) NPC1RAB9AMAPTKDM4EFGFR1
Quinoxaline SCHEMBL10462492 0.75 ALDH1A1 (0.50) NPC1RAB9ALMNAMAPTKDM4E
SCHEMBL5343673 0.72 KDM4C (0.40) MAPTKDM4AKDM4BKDM5CKDM4C
SCHEMBL23143410 0.69 MAPK1 (0.54) SMN1; SMN2NPC1RAB9AMAPK1ADORA3
SCHEMBL23143408 0.69 MAPK1 (0.54) SMN1; SMN2NPC1RAB9AMAPK1ADORA3
SCHEMBL1263213 0.69 EGFR (0.33) HSP90AA1KDM4AKDM4BKDM5CKDM4C
SCHEMBL16878146 0.69 EGFR (0.33) HSP90AA1KDM4AKDM4BKDM5CKDM4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6693121-B2 AS INHIBITORS OF SERINE PROTEASES OF THE COAGULATION CASCADE AND COMPOUNDS, USED FOR ANTICOAGULANT THERAPY FORPROPHYLAXIS OF A VARIETY OF THROMBOTIC CONDITIONS INCLUDING CORONARY ARTERY AND CEREBROVASCULAR DISEASES PHARMACIA CORPORATION 2004-02-17 US disclosed
US-20020032174-A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade PHARMACIA CORPORATION 2002-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020032174-A1 Polycyclic aryl and heteroaryl substituted 4-pyridones useful for selective inhibition of the coagulation cascade TFPI, PLAT, TFPI2 HSP90AA1 4622/4885SMN1; SMN2 3568/4885NPC1 4227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.